Mersana Therapeutics, Inc. - Special Call Transcript

Mar 30, 2020 / 09:00PM GMT
Operator

Good evening, and welcome to Mersana Therapeutics' conference call to review updated XMT-1536 Phase I Dose Escalation Study Data. (Operator Instructions) I would now like to turn the call over to Sarah Carmody, Executive Director, Investor Relations and Corporate Communications. Please proceed.

Sarah Carmody - Mersana Therapeutics, Inc. - Executive Director of IR & Corporate Communications

Good evening, and welcome to our call. A short while ago, we issued a press release detailing the updated clinical data from our ongoing Phase I dose escalation study of XMT-1536. This release as well as the slides we will present today are available on the Investors and Media section of our website at www.mersana.com.

A replay of today's call will also be made available. After our prepared remarks, we will open the call for Q&A. Before I begin, I'd like to mention that our call will contain forward-looking statements within the meaning of federal securities laws. These are not statements of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot